Nuvelo

Nuvelo is a biopharmaceutical company that focuses on the development of novel drugs for the treatment of cardiovascular and cancer diseases. The company was founded in 1993 and is based in San Carlos, California.

History

Nuvelo was originally founded as Hyseq Pharmaceuticals in 1993. The company changed its name to Nuvelo in 2003 after merging with Variagenics. Nuvelo's primary focus is on the development of drugs for the treatment of cardiovascular and cancer diseases.

Products

Nuvelo's product pipeline includes drugs for the treatment of thrombosis, cancer, and inflammation. The company's lead product, alfimeprase, is a direct-acting fibrinolytic that is being developed for the treatment of acute peripheral arterial occlusion (PAO) and catheter occlusion.

Research and Development

Nuvelo's research and development efforts are focused on the discovery and development of novel drugs for the treatment of cardiovascular and cancer diseases. The company's research and development team utilizes a variety of technologies, including genomics, proteomics, and bioinformatics, to identify and validate novel drug targets.

Partnerships

Nuvelo has established partnerships with several pharmaceutical and biotechnology companies to further the development and commercialization of its products. These partnerships provide Nuvelo with additional resources and expertise to advance its product pipeline.

See Also

• Biopharmaceutical
• Cardiovascular disease
• Cancer
• Thrombosis
• Inflammation

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia